Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society (vol 314, pg 1599, 2015)

Kevin Oeffinger, MD, is a family physician, Professor in the Department of Medicine, and a member of the Duke Cancer Institute (DCI). He is founding Director of the DCI Center for Onco-Primary Care, and Co-Director of the DCI Supportive Care and Survivorship Center. He has a long-standing track record of NIH-supported research in cancer screening, early cancer detection, and survivorship. He has published in high impact journals, including the New England Journal of Medicine, Lancet, and JAMA. Dr. Oeffinger is the Duke PI for Pathfinder-2, a multicenter study supported by Grail that is evaluating the utility of Galleri, a multi-cancer early detection blood test (MCED).

Dr. Oeffinger has served in a leadership capacity in various cancer-focused and primary care-focused national committees and organizations, including the American Society of Clinical Oncology, the American Cancer Society, and the American Academy of Family Physicians. He is a past Associate Editor for the Journal of the National Cancer Institute. He is also a member of the Executive Committee for the long-standing NCI-supported Childhood Cancer Survivor Study.

The three-fold mission of the DCI Center for Onco-Primary Care are are to: (1) deliver evidence-based, patient-centered, personalized health care across the cancer continuum by enhancing the interface between cancer specialists and primary care clinicians; (2) conduct innovative research with cutting-edge technology that can be translated to the community setting; and (3) train and educate the next generation of clinicians and researchers to extend this mission.